We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
DCPH

Price
-
Stock movement up
+0.02 (0.08%)
Company name
Deciphera Pharmaceuticals LLC
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
2.21B
Ent value
2.23B
Price/Sales
12.65
Price/Book
7.00
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-4.07%
1 year return
83.05%
3 year return
-8.90%
5 year return
3.14%
10 year return
-
Last updated: 2024-12-17

DIVIDENDS

DCPH does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales12.65
Price to Book7.00
EV to Sales12.73

FINANCIALS

Per share

Loading...
Per share data
Current share count86.48M
EPS (TTM)-2.18
FCF per share (TTM)-1.74

Income statement

Loading...
Income statement data
Revenue (TTM)174.91M
Gross profit (TTM)167.98M
Operating income (TTM)-206.55M
Net income (TTM)-190.42M
EPS (TTM)-2.18
EPS (1y forward)-1.68

Margins

Loading...
Margins data
Gross margin (TTM)96.04%
Operating margin (TTM)-118.09%
Profit margin (TTM)-108.87%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash91.23M
Net receivables32.68M
Total current assets349.94M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment36.08M
Total assets420.93M
Accounts payable19.46M
Short/Current long term debt25.02M
Total current liabilities83.43M
Total liabilities104.88M
Shareholder's equity316.05M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-151.83M
Capital expenditures (TTM)564.00K
Free cash flow (TTM)-152.39M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-60.25%
Return on Assets-45.24%
Return on Invested Capital-59.58%
Cash Return on Invested Capital-47.68%

STOCK INFORMATION

Downside potential

Loading...
Downside potential data
DCPHS&P500
Current price drop from All-time high-63.41%-
Highest price drop-90.18%-56.47%
Date of highest drop7 Mar 20229 Mar 2009
Avg drop from high-48.80%-11.07%
Avg time to new high42 days12 days
Max time to new high1127 days1805 days
COMPANY DETAILS
DCPH (Deciphera Pharmaceuticals LLC) company logo
Marketcap
2.21B
Marketcap category
Mid-cap
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
Employees
355
Investor relations
-
SEC filings
CEO
Steven L. Hoerter
Country
USA
City
Waltham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner